Clinical Research Directory

Inclusion Criteria: * Adults 18 years of age or older * IBS-SSS score \>175 * Meets North American Consensus criteria for H2 SIBO * Willing to take Artecinua™ or placebo as a dietary supplement for 5 weeks * Willing to have two lactulose breath tests and do the prep diet 24 hours before and fast overnight before the test * Willing to have three blood drawstests and fast overnight before the draw * Able to speak, read, and understand English * Able to provide informed consent * For individuals of child-bearing potential, willing to use an intrauterine device or two other concurrent forms of birth control to prevent pregnancy while enrolled Exclusion Criteria: * Use of antibiotic pharmaceuticals or supplements 14 days before baseline breath test * Initiation of change in diet, medication, or supplement regime within 30 days * Hospitalization within the past 3 months * Women who are breastfeeding, pregnant, or planning pregnancy in the next 4 months * Allergies to any of the ingredients in the study products. * Individuals with chronic kidney or liver disease, cancer, colorectal disease and/or other rare disorders that at the discretion of the PI or Clinical \*Investigator may impact their safety or confound trial results * The use of any high-risk medications with narrow therapeutic indices metabolized by CYP450 enzymes: Warfarin (CYP2C9), Tacrolimus/Cyclosporine (CYP3A4), Efavirenz (CYP2B6), and Codeine (CYP2D6). * Drugs requiring activation for efficacy: Clopidogrel (CYP2C19), Codeine (CYP2D6), and Tamoxifen (CYP2D6) (citations). * GFR: \<30 mL/min/1.73m² * Hepatitis from any cause. * Excessive alcohol use (\> seven drinks/week in women and \> fourteen in men). * Hepatic (ALT, AST, bilirubin) and renal (creatinine, estimated GFR) parameters outside of normal range at screening.